GPT and pneumonitis: In comparison to MONARCH 3 (abemaciclib plus anastrozole or letrozole in a similar patient population), patients in cohort 1 experienced increased incidence of all grades (53.8% vs 17.4%) and grade ≥3 ALT increased (42.3% vs 6.4%); all grades (46.2% vs 16.8%) and grade ≥3 AST increased (34.6% vs 3.7%); and all grades (11.5% vs 5.2%) and grade ≥3 ILD/pneumonitis (7.7% vs 1.2%)23.